Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie/J&J's Imbruvica On Track For New Indication In Graft-Versus-Host Disease

Executive Summary

Results suggest 67% objective response rate in second-line+ chronic graft versus host disease; Phase III study is already testing Imbruvica for new onset disease.

Advertisement

Related Content

Safety Issues Not Dampening AbbVie Optimism For Humira Successors
AbbVie’s Cancer Expansion Is Paying Off
AbbVie Makes Further Inroads In Oncology As Humira Loss Looms
J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel